Cholesterol biosynthesis and statins

This talk introduces cholesterol biosynthesis and statins, using it as a basis for further exploration of the fundamentals of cholesterol biosynthesis, including its pathway and stringent regulation in the liver. We will discuss how statins inhibit HMG CoA reductase to lower cholesterol levels and thereby reduce cardiovascular risk. Key clinical uses, benefits, potential side effects, and necessary monitoring of statin therapy will also be addressed. We'll explore the interplay between cholesterol biosynthesis and statins, a cornerstone of lipid lowering therapy. Cholesterol serves critical functions, such as providing membrane fluidity and acting as a precursor a steroid hormones and bile acids. While some cholesterol is absorbed from the diet, most is synthesized in the liver. The synthesis pathway, its regulation, the mechanisms by which statins lower cholesterol, their clinical uses, and considerations for side effects and monitoring will be examined. The cholesterol biosynthesis pathway begins with acetyl coa as the main substrate. Two acetyl coa molecules form acetoacetyl coa, which then joins with another acetyl coa to make HMG coa. HMG coa reductase, catalyzes the conversion to mevalinate the pathways highly regulated rate limiting step. Mevalinate undergoes several reactions to yield isopentanl pyrophosphate, leading to squalene then cholesterol through over 30 enzyme catalyzed steps.